Eli Lilly and Company (LLY) - Comprehensive Stock Analysis Report
📋 Investment SnapshotIs LLY a buy right now? The 10-second read
Reason: Strong business, constructive setup. Expected Return is the upside to the analyst price target; full rationale is detailed below.
📌 Is LLY a Buy right now?
According to Ultra Stock Analysis Pro, Eli Lilly and Company (LLY) is currently rated HOLD (Signal Strength: 3/7 (last fired 2026-08-05, 2d ago)). The long-term fundamentals are strong (P/E: 39.8, Revenue Growth: +47.7%), while short-term technicals show a bullish trend (RSI: 54). Consider waiting for support confirmation near $1189.07 before adding exposure.
Key takeaways
- Rating & timing: rated HOLD (Signal Strength 3/7), model timing GREEN · BULLISH, WATCHING FOR ENTRY · EXTENDED · BREAKOUT FADED.
- Stop loss: the Conservative fixed 2.0x ATR stop sits at $1,101.17, 7.1% below the current $1,185.71.
- Growth vs. valuation: revenue +47.7% YoY with a 54.2% operating margin, at a forward P/E of 25.6x.
- Wall Street: average target $1,292.53 (+9.0%) from 24 Buy, 5 Hold, 2 Sell ratings.
- Key levels: nearest support $1,182.73 (-0.3%), nearest resistance $1,189.07 (+0.3%).
For the latest stock analysis and interactive charts:
📊 Open LLY Analysis ↗
⚡ QUICK DECISIONShould you buy, hold or wait on LLY stock today?
💡 Why This Signal ExistsWhy does LLY carry this rating?
LLY carries a HOLD rating because valuation and fundamentals remain attractive (Investment Quality 84/100), but the trend is weak and consolidating (ADX 18), relative strength has slipped over the past month and only a partial setup is building (Signal Strength 3/7). A breakout above $1189.07 on improving volume would upgrade the signal toward BUY; a break below $1182.73 would mark deeper weakness.
🎯 CONSENSUS HUDWhat is the Wall Street analyst consensus on LLY?
The call itself, and the readings behind it. Details read supportive / caution / headwind.
Action plan
MAINTAIN POSITION — currently -1.9% unrealized. Manage it with the stop levels below.
🎯 Intelligent Stop Loss Strategy
Current Price
$1185.71
Buy Stop Loss
$1101.17
Distance: 7%
Conservative 2.0x
Position Stop Loss
$1080.03
Distance: 9%
Hybrid 2.50x
ATR 14 Day
$42.27
Volatility
ADX Strength
18.5
Weak/No Trend
Position down -2% - Wider stops for recovery
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
🔮 FUTURE PRICE SCENARIOS (AI Forecast)Where could LLY stock go over the next week?
To assist with risk management, here are the three most probable paths for LLY over the next trading week:
🟢 The Bull Case (Probability: 43%)
If LLY reclaims the $1189.07 resistance level, algorithmic targets shift to $1292.53. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 38%)
Failure to hold the $1182.73 support level triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $1074.85 liquidity zone (-9.3% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 18 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $1182.73 and $1189.07 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
⚠️ RISK HUD — DEEP DIVEWhat are the biggest risks of buying LLY now?
Five risk axes scored LOW / MODERATE / HIGH, then the mitigation that follows from them.
📊 BUY-SIDE HUDHow much LLY should you own, and can you trade it at size?
Portfolio-management read: how much to own, what the historical edge is, and whether the position can be traded at size. Details below read supportive / caution / headwind; grey is context, not a verdict.
📈 SELL-SIDE HUDIs LLY stock overvalued or undervalued?
Research read: Eli Lilly and Company · Healthcare · Drug Manufacturers - General. What the business is worth and where the Street stands. Details below read supportive / caution / headwind; grey is context, not a verdict.
🧭 Investment Quality vs. Entry QualityHow does LLY's investment quality compare to its entry quality?
Two independent reads: how good the business is (fundamentals) vs. how stretched the price is against its recent range. Entry Quality is a mean-reversion score — it marks a stock down for trading near the top of its range. It is not the model's timing call, which is GREEN · BULLISH, WATCHING FOR ENTRY · EXTENDED · BREAKOUT FADED and appears in the Consensus HUD above.
Strong on both. LLY pairs a solid business with a constructive setup.
🧮 Factor AttributionWhat is actually driving LLY's rating?
What is driving the view — every factor's signed contribution to one net score. Green adds to the bull case; red detracts.
| Factor | Contribution | Pts |
|---|---|---|
| Earnings Growth +26% YoY | +18 | |
| Profitability Margin 34%, ROE 102% | +16 | |
| Revenue Growth +48% YoY | +10 | |
| Relative Strength +8.8% vs benchmarks (3M) | +9 | |
| Trend EMA bullish, ADX 18 | +5 | |
| Sentiment Bullish | +5 | |
| Valuation Fwd P/E 25.6, PEG 1.5 | +0 | |
| Volatility ATR 3.6% of price | -3 | |
| Momentum RSI 51, MACD bearish | -5 |
Net Factor Score: +55 — Strongly bullish factor profile. This weighs the broad bull/bear case; the entry signal (Signal Strength) governs timing — a strong factor score can still read WAIT until a setup triggers.
🏆 Relative StrengthIs LLY outperforming the S&P 500 and its sector?
The stock's return minus each benchmark's return. Positive = outperforming = leadership; negative = lagging. Relative strength is one of the most durable signals in quantitative research.
| Benchmark | 1-Mo | 3-Mo | 6-Mo |
|---|---|---|---|
| S&P 500 (SPY) | -5.4% | +15.9% | +1.8% |
| Healthcare (XLV) | -4.7% | +6.8% | +8.6% |
| Pharma (XPH) | -3.2% | +3.7% | -10.4% |
LLY 3-month return: +21.8% · Leadership: BROAD LEADER — outperforming the market, its sector, and peers
🤖 ML ProbabilityWhat is the probability LLY stock closes higher?
A gradient-boosted model's estimated probability that price closes higher over each horizon (directional estimate, not a guarantee).
📊 Valuation & Fundamentals vs Drug Manufacturers - General (11 peers)Is LLY cheap or expensive versus its sector peers?
● Top 25% in sector ● Middle 50% ● Bottom 25% — each value colored by its rank among 11 Drug Manufacturers - General peers; "med" is the peer median.
⚔️ LLY vs. Its Closest PeersHow does LLY compare to NVO and its other closest peers?
The closest business match first, then the nearest by market cap within Drug Manufacturers - General from the live sector screener. Industry classification alone is not enough — it files LLY beside companies in a different line of business — so the direct competitor is seeded explicitly. Green marks the best reading in each row, red the worst.
| Metric | LLY (this report) | NVO | JNJ | ABBV |
|---|---|---|---|---|
| Market Cap | $1,056.9B | $208.9B | $624.7B | $434.8B |
| Revenue Growth (YoY) | +47.7% | +2.1% | +6.6% | +10.2% |
| Forward P/E | 25.6x | 14.2x | 21.1x | 15.1x |
| PEG Ratio | 1.49 | 3.20 | 4.28 | 0.40 |
| Operating Margin | 54.2% | 42.5% | 29.2% | 40.0% |
| Trend Strength (ADX) | 18.5 | 22.8 | 17.9 | 26.0 |
NVO (Novo Nordisk A/S — closest business match), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.). Peers marked “closest business match” come from the curated rival map; the rest are the nearest by market cap in the same industry. ADX is shown where recent price data is already on file for that peer.
🎯 ANALYST PRICE TARGETSHow high could LLY go? The full target range
| Average Target: | $1292.53 | High Target: | $1600.00 |
| Current Price: | $1185.71 | Low Target: | $850.00 |
| Upside to Average: | +9.0% | Number of Analysts: | 27 |
🔔 ANALYST RATING CHANGESHave analysts upgraded or downgraded LLY recently?
Recent upgrades, downgrades, and price target changes (last 90 days)
No recent rating changes available
News Sentiment (14-Day)What is the latest news sentiment on LLY?
Overall Score: 4.6/10 - Bullish
Bullish Articles (Top 5 of 6)
- Eli Lilly (LLY) Posts Blowout Growth And Raises Its Outlook
Insider Monkey • Aug 09Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter reve...
Source: https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-... - Eli Lilly (LLY) Gains FDA Breakthrough Nod As Olomorasib Cancer Trial Broadens
Simply Wall St. • Aug 08Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in...
Source: https://finance.yahoo.com/healthcare/articles/eli-lilly-lly-... - Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?
Motley Fool • Aug 08It's not much of a rivalry yet....
Source: https://www.fool.com/investing/2026/08/08/better-glp-1-stock... - Eli Lilly and Company Q2 Earnings Call Highlights
MarketBeat • Aug 08Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabol...
Source: https://www.marketbeat.com/instant-alerts/eli-lilly-and-comp... - These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Arista Beats Views
Investor's Business Daily • Aug 08Amazon.com, Alphabet and Eli Lilly are three of the seven best stocks where investors can find magnificent profit growth prospects. Investors should ...
Source: https://www.investors.com/research/best-stocks-seven-magnifi...
📊 Sentiment Interpretation
The news sentiment is strongly bullish, indicating positive market perception and favorable coverage. This suggests growing investor confidence and potential upward momentum. Consider this as a supporting factor for bullish positions, but verify with technical and fundamental analysis.
📊 Strategy Comparison: Conservative vs Adaptive
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Adaptive adjusts stops based on position profit (tighter as profit grows).
Conservative Strategy
OPEN POSITIONFixed 2.0x ATR Stop Loss
Entry: $1208.12 on 2026-06-26
Confluence: 7/7 (on the entry bar)
Stop Loss: $1101.17
Backtest Results (Since 2018):
Past Win Rate
53%
Past Total Return
+127.4%
Max Drawdown
-11.2%
Avg Trade
+15.1%
Trades
17
Adaptive Strategy
OPEN POSITIONAdaptive ATR Stop Loss (1.0-2.75x)
Entry: $1208.12 on 2026-06-26
Confluence: 7/7 (on the entry bar)
Stop Loss: $1122.30
Backtest Results (Since 2018):
Past Win Rate
54%
Past Total Return
+136.7%
Max Drawdown
-9.2%
Avg Trade
+9.0%
Trades
24
EXECUTIVE SUMMARY - Essential MetricsWhat are the key metrics for LLY stock?
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $1185.71 | Market Cap | $1056.9B |
| Past Win Rate (Backtest) | 52.9% (17 trades) | Forward P/E | 25.6x |
| Past Total Return | +127.4% | Analyst Target | $1292.53 |
| RSI / Trend Strength | 54 / 18 | Upside to Target | +9.0% |
| MACD Signal | Bullish | Revenue Growth | +47.7% |
| Profit Factor | 5.09 | Institutional Own. | 85.4% |
| Position Entry | 2026-06-26 @ $1208.12 | Analyst Ratings | 24 Buy / 5 Hold / 2 Sell |
| Open Position Past P&L | -1.9% |
🤖 ALGORITHMIC CONVICTION & METHODOLOGYHow is the LLY rating calculated?
Why this rating?
The Ultra Stock Analysis algorithm has assigned a HOLD rating to LLY based on a confluence of 3 distinct factors:
- Technical Momentum: The RSI (54) is currently in neutral range in 53% of 17 backtested trades.
- Trend Strength: ADX at 18 indicates weak/consolidating conditions (<20). News sentiment is neutral (Bullish).
- Volatility Profile: The ATR ($42.27) indicates high volatility (3.6% of price), suggesting potential moves of 7.1%+ on breakouts.
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 53% of the time across 17 historical trades over a medium-term (months) hold period, with an average return of +15.1% per trade.
📊 How the Signal Strength score works (and why it can read low in an uptrend)
Signal Strength is a tactical entry-timing score, not a trend or fundamentals grade. It only adds points from setups that flag a fresh reason to enter — breakouts, momentum divergences, and oversold/volume/volatility extremes. Trend direction and fundamentals are scored in their own sections above. A setup must reach 3+ points to register as a signal and 5+ for a strong BUY. Individual boxes below can be checked — a stacked EMA trend alone is worth 2 points — without crossing the 3-point bar; when that happens the registered Signal Strength stays at 3/7, meaning no new entry trigger today — not a bearish call.
| Signal | Pts | What it flags | Now |
|---|---|---|---|
| Valid Breakout | 3 | Close breaks above the 20-day high on >1.5× volume | ✗ |
| EMA Trend Alignment | 2 | EMA20 > EMA50 > EMA200 (stacked uptrend) | ✓ |
| RSI Bullish Divergence | 2 | Price firms while RSI was falling — a reversal setup | — |
| MACD Bullish Divergence | 2 | Price firms while MACD was falling — a reversal setup | — |
| Strong Trend (ADX > 25) | 1 | ADX > 25 confirming the stacked EMAs | ✗ |
| High Volume (>1.5×) | 1 | Volume surge confirming the move | ✓ |
| RSI Oversold | 1 | RSI < 30 — stretched to the downside (bounce setup) | ✗ |
| Below Lower Bollinger | 1 | Close below the lower band (mean-reversion setup) | ✗ |
| Volume Accumulation | 1 | Up-volume divergence — quiet accumulation | — |
This is why LLY can show a bullish EMA trend and solid fundamentals while Signal Strength reads 3/7: those are already-in-trend and value measures, whereas this score fires only on a new tactical setup (an oversold bounce, a divergence, or a high-volume breakout) — none of which is present on the latest bar.
❓ LLY — Common Questions
Every answer below is generated from the same figures as the report above, as of the data date on the cover.
📊 APPENDIX A - Complete Technical Indicators
Comprehensive technical data for quantitative analysis, grouped by what each indicator measures. Price leads; the three Bollinger bands sit together with the band position that reads them.
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Price & Volume | |||
| Current Price | $1185.71 | Volume | 2.9M |
| Avg Volume | 3.0M | Beta | 0.51 |
| Trend | |||
| EMA 20 | $1170.27 | EMA 50 | $1141.66 |
| EMA 200 | $1025.35 | VWAP | $1181.24 |
| Trend Strength (ADX) | 18.49 | Distance from EMA 20 | +1.3% |
| Momentum | |||
| RSI (14) | 53.71 | MACD | 3.26 |
| MACD Signal | 5.92 | MACD Histogram | -2.66 |
| Stochastic %K | 59.71 | Stochastic %D | 40.66 |
| Bollinger Bands (20, 2σ) | |||
| Bollinger Upper | $1225.19 | Bollinger Middle | $1171.16 |
| Bollinger Lower | $1117.12 | Band Position | 63.5% (0% = lower band, 100% = upper) |
| Volatility | |||
| ATR (14) | $42.27 | ATR as % of price | 3.6% |
| Signal | |||
| Confluence Score | 3/7 (last fired 2026-08-05, 2d ago) | Trade Signal | None in the last 30 days |
💼 APPENDIX B - Complete Fundamental Metrics
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $1056.9B | Revenue | $79.7B |
| Forward P/E | 25.6 | Revenue Growth | +47.7% |
| Trailing P/E | 39.8 | Gross Margin | 83.4% |
| Price/Sales | 13.27 | Operating Margin | 54.2% |
| Price/Book | 33.96 | Profit Margin | 33.5% |
| PEG Ratio | 1.49 | ROE | 102.3% |
| Enterprise Value | $1102.8B | Free Cash Flow | $11.1B |
| EPS (Forward) | $46.28 | Dividend Yield | 0.58% |
| 52-Week Range | $625.90 - $1249.45 | ||
📈 APPENDIX C - Complete Trade History & Backtest Results
Comprehensive Trading Performance and Position Details
Backtest Performance Metrics
Current Open Position
| Entry Date | Entry Price | Past P&L | Entry Stop Loss |
|---|---|---|---|
| 2026-06-26 | $1208.12 | -1.85% | $1131.74 |
Recent Trade History (Last 10 Trades)
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2021-09-09 | 2021-09-20 | $229.68 | $221.68 | -3.48% | Loss |
| 2021-10-27 | 2022-01-20 | $239.41 | $233.43 | -2.50% | Loss |
| 2022-03-07 | 2022-04-07 | $252.25 | $297.36 | +17.88% | Win |
| 2022-06-24 | 2022-08-09 | $314.99 | $293.13 | -6.94% | Loss |
| 2022-09-29 | 2024-03-04 | $320.28 | $780.04 | +143.55% | Win |
| 2024-05-21 | 2024-08-02 | $792.11 | $793.38 | +0.16% | Win |
| 2024-08-13 | 2024-11-05 | $895.54 | $796.07 | -11.11% | Loss |
| 2024-11-18 | 2025-04-01 | $719.38 | $797.94 | +10.92% | Win |
| 2025-04-29 | 2025-05-07 | $877.18 | $769.69 | -12.25% | Loss |
| 2025-11-03 | 2026-06-08 | $892.19 | $1149.15 | +28.80% | Win |
Summary: 17 total trades | Strategy: Conservative Stop Loss (Fixed ATR-based)
Run a Live Real-Time Scan of LLY
This report is a snapshot through 2026-08-07. Get current technicals, fresh AI news sentiment, and up-to-the-minute stop-loss levels for LLY — free, no signup.
▶ Run Live LLY Analysis →